This was despite the fact that the work behind the patent, filed in 1997 and granted in 2001, demonstrated that the peptide helped to lower body weight for four weeks in type 2 diabetes patients who were obese (DiMarchi, Efendic)
When to Seek Guidance from a Pharmacist or Prescriber Anyone who has obtained retatrutide from an unregulated source, experiences adverse effects, or has concerns about product integrity should consult their GP, pharmacist, or trial team before use, and report issues via the MHRA Yellow Card scheme
Conclusion GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF
There is no official maintenance dose for retatrutide yet because it is still being studied and has not been approved
Clinicians overseeing trial participants assessed each individual's response and tolerability before proceeding to the next dose level
It can also help manage obstructive sleep apnea